Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

BACKGROUND: MMR II (M-M-R II [Merck & Co, Inc.]) is currently the only measles, mumps, and rubella (MMR) vaccine licensed in the United States. A second MMR vaccine would mitigate the potential risk of vaccine supply shortage or delay. In this study, we assessed the immunogenicity and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Nicola P, Abu-Elyazeed, Remon, Povey, Michael, Macias Parra, Mercedes, Diez-Domingo, Javier, Ahonen, Anitta, Korhonen, Tiina, Tinoco, Juan-Carlos, Weiner, Leonard, Marshall, Gary S, Silas, Peter E, Sarpong, Kwabena O, Ramsey, Keith P, Fling, John A, Speicher, David, Campos, Maribel, Munjal, Iona, Peltier, Christopher, Vesikari, Timo, Baccarini, Carmen, Caplanusi, Adrian, Gillard, Paul, Carryn, Stephane, Henry, Ouzama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192400/
https://www.ncbi.nlm.nih.gov/pubmed/30849175
http://dx.doi.org/10.1093/jpids/piz010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192400/
https://www.ncbi.nlm.nih.gov/pubmed/30849175
http://dx.doi.org/10.1093/jpids/piz010

Ejemplares similares